Urology, Genetics and Precision Medicine

01Purpose and scope

• This manual supports the course Urology, Genetics and Precision Medicine. It is written for urologists, advanced practice clinicians, residents, genetic counselors, pathologists, and laboratory staff who work where kidney, bladder, prostate, testicular, and penile conditions meet inherited risk, tumor biology, or drug response. It describes how the work is actually done in clinics, tumor boards, and laboratories, not how it is described in a textbook chapter.
• The scope covers four areas: identifying patients whose history or tumor features justify genetic evaluation, ordering and interpreting germline and somatic tests, using results to guide treatment choices such as systemic therapy for advanced prostate or urothelial cancer, and communicating findings to patients and relatives. It does not cover every rare kidney disorder or the full technical design of sequencing pipelines. Those topics belong to nephrology texts and laboratory standard operating procedures.
• This guidance does not replace qualified professional judgment, approved institutional procedures, or any required authorization for testing or treatment. Clinical genetics and oncology are regulated and high-risk fields. Local laboratory directories, payer policies, and professional society guidelines change, so confirm current criteria with the authoritative source in your jurisdiction before acting.

02Core principles

• Start with the patient history, not the test. A family history of early prostate, kidney, or colorectal cancer, or a personal history of multiple primary tumors, usually matters more than any single laboratory result. A detailed three-generation pedigree, recorded with ages at diagnosis and cancer types, is often the most useful tool available in the first visit.
• Separate germline testing from somatic testing. Germline testing looks for inherited variants present in every cell and informs the patient and relatives. Somatic testing looks for variants present only in the tumor and mainly guides therapy. A result from one test type does not answer the question of the other, and the report should say which one was performed.
• Treat variant classification as provisional. Most laboratories use a standard five-tier framework for reporting variants, such as the ACMG and AMP variant classification guidelines, which sort findings into pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. Variants of uncertain significance should not drive surgery, prophylactic decisions, or cascade testing on their own, and they should be re-reviewed as databases change.
• Precision medicine works through decisions, not through a test panel. A result is useful only if it changes a decision the patient and clinician can actually make, such as active surveillance versus intervention, eligibility for a targeted agent, screening intensity for relatives, or selection of a drug dose based on metabolism.

03Planning and preparation

• Before ordering, confirm the indication. Common urology indications for germline testing include metastatic or high-risk prostate cancer, early-onset prostate cancer with a family history, renal cell carcinoma in young patients or with bilateral or multifocal disease, and urothelial cancer with a suspected Lynch syndrome pattern. Many professional societies publish criteria for these groups, and the criteria are revised periodically, so check the current version used by your institution.
• Decide who consents and who counsels. Pretest counseling should explain what the test can and cannot show, the likelihood of a clinically actionable result, possible incidental findings, and what happens to results over time. Where a genetic counselor or clinical geneticist is available, refer early, because counseling time is limited and results can arrive weeks later.
• Prepare the material before the appointment. Collect prior pathology reports, operative notes, staging imaging summaries, and any existing genetic results. For somatic testing, confirm that tissue blocks or a recent biopsy are available and that tumor content is adequate for the assay. Laboratories often reject specimens with low tumor fraction, and that delay can push treatment back by weeks.

04Recommended workflow

1. 1
   : Take a structured family history and record cancers by relative, type, and age at diagnosis. Ask about known pathogenic variants in the family, prior genetic testing, and ancestry where relevant, because some founder variants are more common in particular populations. Record the information in a format the genetic counselor can reuse.
2. 2
   : Confirm the indication against current criteria and decide between germline testing, somatic testing, or both. For advanced prostate cancer, many clinicians order germline and somatic tests together so that therapy selection and family implications are addressed at the same time. Document the rationale in one sentence.
3. 3
   : Obtain informed consent after pretest counseling. Confirm that the patient understands that results may affect relatives, that insurance coverage and privacy protections vary, and that a negative result does not rule out inherited risk when the family history is strong. Record who was present and what questions were answered.
4. 4
   : Order the test with complete clinical information. Include tumor type, histology, stage, prior therapies, and the specimen source. Laboratories use this information for interpretation, and an incomplete requisition is a common cause of reports that are technically correct but clinically vague.
5. 5
   : Review the report with a qualified professional before discussing it with the patient. Check the variant classification, the gene panel content, the assay limitations, and any statement about unresolved findings. Confirm whether a result changes treatment, surveillance, or cascade testing, and note any findings that need repeat testing or specialist review.
6. 6
   : Disclose results in person or by a method your policy allows, then arrange follow-up. Results should be discussed with time for questions, with written materials and a referral to a genetic counselor for relatives. Schedule the next clinical decision, such as a surveillance interval or a tumor board review, before the patient leaves.

05Quality checks, risk controls and compliance

• Check that every result has been matched to the correct patient and specimen before it is acted upon. Two identifiers should be confirmed at ordering, at specimen receipt, and at result review. Mismatched tumor and normal samples are rare but serious, and a second look at the accession numbers is cheap insurance.
• Control the risks of overinterpretation and underinterpretation. Overinterpretation happens when an uncertain variant is treated as a diagnosis and leads to unnecessary prophylactic surgery or family anxiety. Underinterpretation happens when a clinically relevant result is filed without action, for example a mismatch repair deficient tumor that was not referred for germline evaluation. Both risks are reduced by scheduled re-review of results and by a named clinician responsible for each report.
• Comply with the privacy and nondiscrimination rules that apply where you practice. In the United States, the Health Insurance Portability and Accountability Act governs use of health information, and the Genetic Information Nondiscrimination Act restricts certain uses of genetic information by health insurers and employers, but it does not cover life, disability, or long-term care insurance. Other countries and states have their own laws. Confirm the current requirements with your compliance office and the authoritative regulator in your jurisdiction.

06Collaboration and documentation

• The core team usually includes the urologist or oncologist, a genetic counselor or clinical geneticist, a pathologist or molecular laboratory director, and a nurse or coordinator who tracks results. Tumor boards are the usual forum for discussing somatic findings and therapy options. Decide in advance who owns the result, who contacts the patient if the result is delayed, and who records the final plan.
• Document the indication, consent, pretest counseling, the test ordered, the report version, the classification of each reported variant, the discussion with the patient, and the plan for relatives. Notes should state what was decided and why, not only what was done. A future clinician reading the chart should be able to tell whether a result was reviewed and what it changed.
• Keep a clear record of results that remain open. Variant reclassification can occur years after the original test, and the laboratory may send an updated report that no one reads. Assign a person to monitor reclassification notices or to run periodic reanalysis for patients with unresolved findings. Notify the patient and the referring clinician when a classification changes.

07Measures and continuous improvement

• Track a small set of indicators that reflect the workflow. Useful measures include the proportion of eligible patients who had germline or somatic testing documented, the time from order to result, the time from result to disclosure, the proportion of pathogenic findings that led to a documented management change, and the rate of testing failures from inadequate tumor content. Set targets locally, since published benchmarks vary by setting and population.
• Review cases where the process failed, such as a delayed result that missed a treatment window or a relative who was never offered testing. Look for patterns in the requisition, consent, and handoff steps rather than blaming individuals. A short monthly review of a random sample of charts often reveals more than a large annual audit.
• Reassess the criteria and pathways every time a guideline or laboratory policy changes. Keep a local summary of current indications, the contacts for counseling and laboratory questions, and the forms used for consent. The summary should name the version and the owner, so that outdated versions are retired.

08Common mistakes and how to prevent them

• A frequent mistake is ordering a multigene panel without a clear question. Broad panels return many variants of uncertain significance and incidental findings that the patient may not have wanted. Prevent this by writing the specific clinical question on the requisition and by limiting the gene list to the indication, unless the patient has agreed to broader reporting.
• Another mistake is treating a negative result as reassurance when family history remains strong. A negative test for a single gene does not exclude inherited risk if other genes or unidentified variants could explain the family pattern. Document the family history interpretation alongside every negative result and plan appropriate screening regardless.
• A third mistake is failing to communicate results to relatives. Patients often intend to tell their families but do not, and the window for early detection may pass. Provide a letter or a referral that the patient can share, and offer a genetic counselor visit for at-risk relatives. Record whether the offer was made and accepted.

09Practical checklist

• Confirm the indication against the current criteria your institution uses before ordering any test.
• Take a three-generation family history with ages and cancer types, and record it in the chart.
• Decide whether the question is germline, somatic, or both, and write that decision on the requisition.
• Complete pretest counseling and document consent, including how results may affect relatives.
• Verify patient identity and specimen identity at ordering, receipt, and result review.
• Review the report with a qualified professional, check variant classifications, and note assay limits.
• Document the disclosure, the management decision, the family plan, and a date-free follow-up trigger for reanalysis.

★Learning sources

• Micro Degree: Urology, Genetics and Precision Medicine
• Micro Degree: Healthcare Administration Practice
• Micro Degree: Physiotherapy Assistant Operations
• Micro Degree: Cardiac Care Support